Guided Therapeutics Inc

Guided Therapeutics Inc has a negative equity position of $6.01 million and a debt-to-equity ratio of -0.37, indicating a capital structure heavily reliant on debt financing. The company's liquidity is constrained, with a current ratio of 0.09 and only $63,000 in cash and equivalents, which is insufficient to cover its $7.33 million in total liabilities. The negative operating and free cash flows of $1.07 million and $3.34 million, respectively, suggest ongoing cash burn and limited ability to fund operations without external financing. Profitability metrics are weak, with a net loss of $3.20 million and an operating loss of $2.81 million. The return on equity of 53.21% is misleading due to the negative equity base, and the return on assets of -2.41% reflects poor asset utilization. These figures fall significantly below the industry median for profitability and returns, which typically show positive net income and higher asset efficiency. The company's revenue is concentrated in a single product, the LuViva device, with no disclosed geographic diversification. This lack of segment or geographic diversification increases exposure to market-specific risks, such as regulatory changes or adoption rates in key markets. The absence of multiple revenue streams or geographic regions in the financial snapshot suggests a high concentration risk. The company's growth trajectory is uncertain, with no disclosed revenue growth in the latest period. The outlook for the current fiscal year does not indicate a reversal of the negative operating and free cash flows, and the absence of a next fiscal year forecast suggests limited visibility into future performance. The company's capital expenditures are minimal, indicating a lack of investment in growth initiatives. The risk assessment highlights liquidity as a medium concern, with the company's cash position insufficient to cover its liabilities. The dilution risk is low, as the number of shares outstanding has not changed between basic and diluted shares. However, the negative net cash position after subtracting total debt indicates a potential need for further financing, which could lead to future dilution. The company has not disclosed any recent financing events or share issuance plans. Recent events include the continued focus on the LuViva device and the company's efforts to market it as a non-invasive alternative to traditional cervical cancer screening. No recent filings or transcripts indicate significant changes in strategy or new product development. The company's 10-K filing for 2023 provides the most recent financial and operational update.